Bai Y H, Zhang Z, Li S P
Department of Biological Products, Chaoyang District Center for Disease Prevention and Control of Beijing, Beijing 100020, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 May 6;56(5):659-667. doi: 10.3760/cma.j.cn112150-20211119-01072.
Coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has spread all over the world. Streptococcus pneumoniae as a common pathogen of community-acquired pneumonia shares similar high-risk susceptible populations with COVID-19. Streptococcus pneumoniae co-infection is a key risk factor for severe COVID-19 and death. Pneumococcal vaccination has a beneficial impact on reducing the incidence and mortality of COVID-19. The vaccination rate of streptococcus pneumoniae is still low in China. Streptococcus pneumoniae vaccination may be one of effective strategies in the management of COVID-19 for high-risk population such as the elderly and those who have underlying chronic diseases.
由严重急性呼吸综合征冠状病毒 2 引起的冠状病毒病 19(COVID-19)已在全球蔓延。肺炎链球菌作为社区获得性肺炎的常见病原体,与 COVID-19 有相似的高危易感人群。肺炎链球菌合并感染是重症 COVID-19 和死亡的关键危险因素。肺炎球菌疫苗接种对降低 COVID-19 的发病率和死亡率有有益影响。中国肺炎链球菌的疫苗接种率仍然较低。肺炎球菌疫苗接种可能是对老年人和患有基础慢性病等高危人群进行 COVID-19 管理的有效策略之一。